Lantern Pharma Inc. LTRN
0.50 USD -0.10 (-17.28%)
Nov 10, 2026, 1:37 PM EST
0.5001 Day range 0.67495
0.50 52-week range 4.34
- YTD
- -83.47%
- 1 year
- -85.89%
News
benzinga.com Lantern Pharma's Stralight Therapeutics Publishes LP-184 Phase 1a GBM Data, Establishing The Recommended Dose For Expansion And A Clinically Translatable Dosing Strategy For The Planned Phase 1b/2a Trial Publication in Cancer Research Communications establishes the recommended dose for expansion and a clinically translatable dosing strategy for the planned Phase 1b/2a trial (NCT07431216)LP-184 was…
businesswire.com Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, and its wholly owned subsidiary Starlight Therapeutics today announced the…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market session. The company's market cap stands at $4.5 million. AIxCrypto Hldgs (NASDAQ:AIXC) stock moved…
benzinga.com Lantern Pharma Issued Notice Of Allowance From U.S. Patent And Trademark Office For Application Titled Method For Treating Blood Cancers Lantern Pharma Inc. (NASDAQ:LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States…
benzinga.com Lantern Pharma Q2 2026 Earnings Call: Complete Transcript Lantern Pharma (NASDAQ:LTRN) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to…
benzinga.com Lantern Pharma Q2 EPS $(0.57) Misses $(0.38) Estimate Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.38) by 50 percent. This is a 42.5 percent decrease over losses of…
benzinga.com Lantern Pharma Creates Open-Medicine AI As Separate Entity Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing…- benzinga.com Lantern Pharma Announces EMA Clearance Of An Investigator-Initiated Phase 1b/2 Clinical Trial Of LP-184 In Advanced, Recurrent Bladder Cancer The study will be conducted at Rigshospitalet in Copenhagen — Denmark’s national referral center for urologic cancers — in collaboration with Professor Helle Pappot, MD, DMSc, a leading authority in…
benzinga.com Lantern Pharma Receives Notice Of Allowance From U.S. Patent And Trademark Office For 'Methods For The Treatment Of Solid Tumor Cancers Using Illudins And Biomarkers' The United States Patent and Trademark Office has issued Lantern Biopharma a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics…
benzinga.com Lantern Pharma Launches ZetaOmics, A Computational-Biology Module Of Its WithZeta.ai Co-Scientist Platform ZetaOmics introduces an autonomous "Computational Biologist" persona (agent) that performs real, end-to-end bioinformatics and multi-omic analysis — across any cancer type, and is purpose-built for…
benzinga.com Lantern Pharma Reports Clinical Data And Updates From Ongoing Phase 2 HARMONIC Trial Evaluating LP-300 In Combination With Carboplatin And Pemetrexed In Patients With EGFR Exon 21 L858R-Mutant NSCLC Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile.PFS benefit deepens…- benzinga.com Lantern Pharma Receives Successful Response To Its Recent FDA Type C Meeting Request Focused On The Ongoing Phase 2 HARMONIC Trial Of LP-300 In Never-Smokers With Advanced Non-Small Cell Lung Cancer Adenocarcinoma In its written responses to Lantern's Type C meeting request, the FDA raised no objections to key proposed protocol amendments, providing a more focused, clearer regulatory path forward for the…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Lantern Pharma Q1 EPS $(0.30) Beats $(0.36) Estimate Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 28.57 percent increase over losses of…
benzinga.com Earnings Scheduled For May 15, 2026 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Lantern Pharma Announces Up To $9.25M Direct Offering With Existing Shareholders And Unnamed Institutional Investor; Transaction Expected To Close May 14 Lantern Pharma announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,135,923 shares of its common stock (or pre-funded warrants in lieu thereof) at…
benzinga.com Lantern Pharma Expands Its predictBBB.ai Web Service Into A Large Quantitative Model For the first time, pharmaceutical scientists and medicinal chemists can access a unified, benchmark-validated LQM — not as a batch software installation, not as a siloed cheminformatics tool — but…- benzinga.com Lantern Pharma Plans First Public Demonstration Of withZeta.ai, Its Multi-Agentic AI Co-Scientist Platform On April 30 The event follows the platform's scientific community debut at the American Association for Cancer Research (AACR) Annual Meeting 2026 and its initial unveiling at Nasdaq MarketSite — and marks the…
- benzinga.com Lantern Pharma Schedules FDA Type C Meeting To Refine HARMONIC Trial For LP-300 In EGFR L858R NSCLC, Highlighting Progression-Free Survival Signals Lantern Pharma Schedules Type C Meeting with the FDA to Advance HARMONIC™ Protocol Amendments Targeting This High-Need Population, Reflecting LP-300's Novel Mechanism of Action and the Rapidly…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Lantern Pharma Q4 EPS $(0.36) Beats $(0.46) Estimate Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.46) by 21.74 percent. This is a 33.33 percent increase over losses of…
benzinga.com Why Is Lantern Pharma Stock Soaring Monday? Lantern Pharma shares rebound in premarket trading as the company debunks a false report regarding CEO Panna Sharma's departure.- benzinga.com Earnings Scheduled For March 30, 2026
benzinga.com Why PMGC Holdings Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket PMGC Holdings shares surged 100.6% to $3.35 in pre-market trading after announcing a licensing agreement amendment for its clinical development program. Gainers include ITRM, ZNB, and GV; Losers…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Lantern Pharma And Starlight Therapeutics Say FDA Clears IND Application For STAR-001 In Planned Phase 1 Pediatric Clinical Trial The Planned Multicenter Phase 1 Trial Will Evaluate STAR-001 as Monotherapy and in Combination with Spironolactone in Children with Relapsed or Refractory CNS Malignancies, Including ATRT, DIPG, GBM,…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Lantern Pharma Announces Establishment Of A.I. Center Of Excellence And Advanced Agentic Labs In Bengaluru, India The A.I. Center of Excellence is planned to be based in Bengaluru and focus on large scale data-engineering, development and refinement of state-of-the-art ML-ready disease models and integration…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Lantern Pharma Q3 EPS $(0.39) Beats $(0.54) Estimate Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.54) by 27.78 percent. This is a 7.14 percent increase over losses of…
benzinga.com Lantern Pharma Earnings Preview - benzinga.com Lantern Pharma To Showcase Two Of Its Commercially Deployed AI Research Platforms At The Inaugural AI For Biology And Medicine Symposium At The University Of North Texas Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs.predictBBB.ai and LBx-AI,…
- benzinga.com Lantern Pharma Presents Clinical Data From Ongoing Phase 1 Trial Of LP-284, At LL&M Congress, Featuring Metabolic Response In Aggressive DLBCL Case After Multiple Failed Therapies AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific antibody therapies, validating LP-284's mechanism of action.A novel…
- benzinga.com Lantern Pharma's LP-184 Meets All Phase 1a Endpoints, Shows Clinical Benefit In Hard-to-Treat Cancers And Advances To Phase 2 Trials LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both monotherapy or synergistic combinations with PARP inhibitors and…
- benzinga.com Lantern Pharma Completes Type C Meeting With FDA, Advancing Pediatric CNS Cancer Trial Including Atypical Teratoid Rhabdoid Tumor Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that are being advanced using its proprietary computational biology and…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Lantern Pharma Q2 EPS $(0.40) Beats $(0.48) Estimate Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 17.53 percent. This is a 13.04 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Lantern Pharma's Starlight Therapeutics Receives FDA Clearance Its IND For Phase Ib/2a Glioblastoma Multiforme Trial Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progressionGBM represents an annual market opportunity of $3 to $5 billion USD with an…
- benzinga.com Lantern Pharma Unveils PredictBBB.ai With 94% Accuracy, Revolutionizing CNS Drug Development Through Real-Time AI Industry-Leading Platform Achieves 94% Accuracy with Real-Time Machine Learning, Providing Open-Access to Critical CNS Drug Development TechnologyAdditional Predictive, Analytic and Descriptive…
- benzinga.com Lantern Pharma Completes Early Enrollment in Japan for Lung Cancer Trial Targeting Never-Smokers Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced the successful completion of…
- benzinga.com Lantern Pharma Reports Complete Metabolic Response In A Heavily Pre-Treated Lymphoma Patient With LP-284 In Its Phase 1 Clinical Trial AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prior state-of-the-art treatment regimens.Complete response in an…
- benzinga.com Lantern Pharma Secures EU Patent Allowance For LP-284, Expanding Global IP For B-Cell Lymphoma Therapy The EU patent allowance strengthens the prior patent allowance for LP-284 in the US, Japan India and Mexico.LP-284 has the potential to address B-cell lymphomas and other B-cell driven malignancies…
- benzinga.com Lantern Pharma Launches AI Module Trained On 221 Clinical Trials To Predict Efficacy Of DNA-Damaging Agent Combinations; Platform Already Guided FDA-Cleared Phase 1B/2 Trial In Triple-Negative Breast Cancer The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern's AI platform, RADR ®, and will initially focus on tailored combinations of DNA damaging agents and DNA repair